» Articles » PMID: 38658140

COVID-19 Clinical Trial Participation and Awareness in Texas

Overview
Date 2024 Apr 24
PMID 38658140
Authors
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic required the rapid development of COVID-19 vaccines and treatments, necessitating quick yet representative clinical trial enrollment to evaluate these preventive measures. However, misinformation around the COVID-19 pandemic and general concerns about clinical trial participation in the U.S. hindered clinical trial enrollment. This study assessed awareness of, willingness to participate in, and enrollment in COVID-19 vaccine and treatment clinical trials in Texas. A quota sample of 1,089 Texas residents was collected online from June - July 2022. Respondents were asked if they were aware of, willing to participate in, and had enrolled in clinical trials for COVID-19 vaccines or treatments. Overall, 45.8% of respondents reported being aware of clinical trials for COVID-19 treatments or vaccines, but only 21.7% knew how to enroll and only 13.2% had enrolled in a COVID-19 clinical trial. Respondents with bachelor's or graduate degrees were more likely to be aware of clinical trials, more likely to have enrolled in trials, and more willing to participate in treatment trials. Women were less willing to participate and less likely to have enrolled in COVID-19 clinical trials than men. Respondents aged 55 years and older were more willing to participate, but less likely to have enrolled in COVID-19 clinical trials than 18-to-24-year-olds. Common reasons given for not participating in clinical trials included concerns that COVID-19 treatments may not be safe, government distrust, and uncertainty about what clinical trial participation would entail. Substantial progress is needed to build community awareness and increase enrollment in clinical trials.

Citing Articles

Predictors of willingness to participate in COVID-19 clinical trials among Black and Latino adults.

Weston C, Andrade E, Olawole W, Guerrero Vazquez M, Miller H, Stevens S J Clin Transl Sci. 2025; 8(1):e217.

PMID: 39823111 PMC: 11736297. DOI: 10.1017/cts.2024.654.

References
1.
Ellis P, Butow P, Tattersall M, Dunn S, Houssami N . Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol. 2001; 19(15):3554-61. DOI: 10.1200/JCO.2001.19.15.3554. View

2.
Hughes-Morley A, Young B, Waheed W, Small N, Bower P . Factors affecting recruitment into depression trials: Systematic review, meta-synthesis and conceptual framework. J Affect Disord. 2014; 172:274-90. DOI: 10.1016/j.jad.2014.10.005. View

3.
Gottlieb S . The Need for a US National Clinical Trial Infrastructure in a Public Health Crisis. JAMA Health Forum. 2022; 2(8):e213223. DOI: 10.1001/jamahealthforum.2021.3223. View

4.
Rivers D, August E, Sehovic I, Green B, Quinn G . A systematic review of the factors influencing African Americans' participation in cancer clinical trials. Contemp Clin Trials. 2013; 35(2):13-32. DOI: 10.1016/j.cct.2013.03.007. View

5.
Gotay C . Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991; 33(5):569-77. DOI: 10.1016/0277-9536(91)90214-w. View